Find Oncology Drugs in Phase I/II Clinical Development in UNITED KINGDOM

Lead Product(s): SCIB1

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

Scancell will initiate the US arm of the Phase 2 clinical trial of SCIB1 in patients with metastatic melanoma, receiving the checkpoint inhibitor pembrolizumab, using Ichor’s TriGrid® .

Lead Product(s): AUTO3,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Initial data show encouraging clinical activity with manageable safety profile. No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab.